<DOC>
	<DOCNO>NCT00369928</DOCNO>
	<brief_summary>This 12-week , double-blind , randomize , placebo-controlled , parallel group , multicenter study evaluate safety , efficacy , PK oral administration PG-760564 adult patient active RA receiving treatment MTX . Two oral dos PG-760564 evaluate : 25 mg BID 100 mg BID . The study consist screen visit follow washout period disease modify antirheumatic drug ( DMARDs ) anti-cytokine therapy except MTX . After washout period , patient determine eligible randomize receive either 25 mg BID 100 mg BID oral PG-760564 , placebo 12 week . There 6 treatment visit follow-up visit 4 week last treatment visit . The primary efficacy endpoint proportion patient meet ACR 20 response criterion 12 week treatment .</brief_summary>
	<brief_title>Evaluation 2 Oral Doses PG-760564 Rheumatoid Arthritis ( RA ) Patients Receiving Methotrexate</brief_title>
	<detailed_description>The study conduct North America Europe approximately 50 60 site . Approximately 270 patient randomize , 189 expect complete study . The study consist screen visit follow washout period disease modify antirheumatic drug ( DMARDs ) anti-cytokine therapy except MTX . The washout period 4 week sulfasalazine , hydroxychloroquine , azathioprine , D-penicillamine , etanercept , anakinra , 8 week gold , infliximab , adalimumab , 12 week abatacept . After washout period , patient determine eligible randomize receive either 25 mg BID 100 mg BID oral PG-760564 , placebo 12 week . There 6 treatment visit ( Weeks 1 , 2 , 4 , 6 , 8 , 12 ) follow-up visit 4 week last treatment visit ( Week 16 ) . Patients initiate new therapy 4-week follow-up complete . Liver function test evaluate every visit . The primary efficacy endpoint proportion patient meet ACR 20 response criterion 12 week treatment .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Meet American College Rheumatology ( ACR ) criteria Rheumatoid Arthritis Disease duration least 6 month Must treat Methotrexate least 24 week At least 6 swollen joint 6 tender joint Washout required Disease Modifying Antirheumatic Drugs ( DMARDs ) Women childbearing age male must use acceptable method birth control Tuberculosis Malignancies Abnormal electrocardiograms describe protocol Current infection recurrent infection immunodeficiency Liver diseases abnormality liver function test describe protocol Autoimmune diseases RA except Sjogren 's syndrome secondary RA ; History demyelization diseases Any condition opinion investigator could detrimental patient enrol study include clinically important change laboratory value diseases describe protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>